Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study

Progress in Neuro-psychopharmacology & Biological Psychiatry
Chi-Un PaePrakash Masand

Abstract

This study evaluated the overall effectiveness and tolerability of atypical antipsychotics (risperidone vs. olanzapine vs. quetiapine) used in the treatment of bipolar inpatients. After screening 463 patients, the medical records of 158 inpatients with bipolar I disorder, who were given olanzapine, risperidone or quetiapine as adjuncts to mood stabilizers for at least 1 month and not administered with any other antipsychotics, were examined. Details of the tolerability and effectiveness were reviewed according to the treatment records during their hospital stay. The results showed equivalent effectiveness based on the Clinical Global Impression (CGI) and Global Assessment Functioning (GAF) score between the three atypical antipsychotics. The frequency of the extrapyramidal symptom-related side effects were higher in the risperidone-treated group than in the olanzapine and quetiapine-treated group. This suggests that risperidone, olanzapine and quetiapine have a comparable effectiveness in inpatients with bipolar I disorder in a naturalistic setting. However, there were some differences in tolerability between these results as reported from previous Western studies.

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Sep 1, 1995·The American Journal of Psychiatry·D A Patterson, M S Lee
Dec 24, 1997·Comprehensive Psychiatry·S N GhaemiC J Truman
Jul 13, 1999·The Journal of Clinical Psychiatry·K N ChengappaN R Schooler
Mar 1, 2000·The Journal of Clinical Psychiatry·C A Zarate, M Tohen
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Mar 12, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Prakash S. MasandAhmad Hameed
Jun 1, 2004·The American Journal of Psychiatry·Robert M A HirschfeldFred Grossman
Nov 13, 2004·Journal of Clinical Psychopharmacology·Lakshmi N YathamAnd Mårten Vågerö
Nov 13, 2004·Current Psychiatry Reports·Daniel Z Lieberman, Frederick K Goodwin
May 3, 2005·The American Journal of Psychiatry·Christopher BaethgeMauricio Tohen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here